Iris Löw-Friedrich
- Role
-
Board member
Elected to the Board in 2026 and regarded as an independent board member.
- Member of the Remuneration Committee
- Member of the Scientific Committee
Special competencies
Former Chief Medical Officer and Global Head of Development at UCB (2008–2024), Executive Committee member with end‑to‑end leadership of global clinical development, medical, regulatory, safety, and quality functions.
Led the worldwide development and launch of 10+ new molecular entities across immunology, neurology, and bone diseases, spanning small molecules, biologics, and genetic medicines, with deep expertise in benefit–risk stewardship.
Seasoned board‑level leader with broad experience in life sciences governance, innovation, M&A, and advisory roles across biotech, pharma, and research institutions.
Current positions
-
Chair of the Board of Celosia Therapeutics pty Ltd.
-
Member of the Board of Fresenius SE & Co. KGaA
-
Member of the Board of Satellos Bioscience Inc.
-
Member of the Board of Sobi (Swedish Orphan Biovitrum AB)
-
Member of the Board of Financière de Tubize
